Drug Trial Radar · NCT02967692
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
568
Actual
Start
Feb 17, 2017
Primary completion
Aug 11, 2020
Study completion Aug 21, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.
Conditions
- Melanoma
Interventions
SpartalizumabBiological
Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
PlaceboOther
Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
DabrafenibDrug
Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
TrametinibDrug
Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 8 weeks (Part 1)
- Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and TrametinibTime frame: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
- Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and TrametinibTime frame: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
- Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1Time frame: Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)
Locations
179 sites in 29 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research and Excellence
Encinitas, California
UC Irvine Medical Center
Orange, California
California Pacific Medical Center
San Francisco, California
Stanford Cancer Center
Stanford, California
University of Kansas Cancer Center
Westwood, Kansas
Johns Hopkins U
Lutherville, Maryland
Nebraska Cancer Specialists
Omaha, Nebraska
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York
University of Pittsburgh Med Center
Pittsburgh, Pennsylvania
University of Tennessee Medical Ctr
Knoxville, Tennessee
Univ of TX MD Anderson Cancer Cntr
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Gateshead, New South Wales, Australia
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Greenslopes, Queensland, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Sankt Pölten, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Rio de Janeiro, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Santiago, Chile
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.